Cargando…
Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice
The increased PD-L1 induces poorer prognosis in melanoma. The treatment with PD-1/PD-L1 antibodies have a low response rate. The combination immunotherapies are the encouraging drug development strategy to receive maximal therapeutic benefit. In this study, we investigated the enhanced antitumor and...
Autores principales: | Hu, Zhengping, Ye, Liang, Xing, Yingying, Hu, Jinhang, Xi, Tao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760644/ https://www.ncbi.nlm.nih.gov/pubmed/29317734 http://dx.doi.org/10.1038/s41598-017-18641-y |
Ejemplares similares
-
PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice
por: Hu, Zhengping, et al.
Publicado: (2020) -
Correction: PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice
Publicado: (2021) -
Electrotransfer of Different Control Plasmids Elicits Different Antitumor Effectiveness in B16.F10 Melanoma
por: Bosnjak, Masa, et al.
Publicado: (2018) -
Advantages of FBPA PET in evaluating early response of anti-PD-1 immunotherapy in B16F10 melanoma-bearing mice: Comparison to FDG PET
por: Tatsumi, Mitsuaki, et al.
Publicado: (2022) -
Xanthomicrol Exerts Antiangiogenic and Antitumor Effects in a Mouse Melanoma (B16F10) Allograft Model
por: Ghazizadeh, Foad, et al.
Publicado: (2020)